Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study Meeting Abstract
| Authors: | Choueiri, T. K.; Albiges, L.; Tomczak, P.; Suáez, C.; Voss, M. H.; de Velasco, G.; Chahoud, J.; Procopio, G.; Mahammedi, H.; Zengerling, F.; Kim, C.; Gupta, S.; Bergthold, G.; Liu, B.; Kalaitzidou, M.; Huseni, M. A.; Scheffold, C.; Powles, T.; Pal, S. K. |
| Abstract Title: | Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 17 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-10 |
| Language: | English |
| ACCESSION: | WOS:001043181100024 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2023.41.17_suppl.LBA4500 |
| Notes: | Meeting Abstract: LBA4500 -- Meeting was also available virtually -- Source: Wos |
